Table 1.
Physician Demographics1
| Investigators (N = 124) | |
|---|---|
| Median (range) time in clinical practice, years | 12.0 (1−35) |
| Median (range) patients treated in clinic per month, n | 350 (12−999) |
| Primary specialty, n (%) | |
| Hematologist/oncologist | 99 (80) |
| Oncologist | 23 (19) |
| Gynecologist/oncologist | 2 (2) |
| Type of clinical practice, n (%) | |
| Single specialty | 82 (66) |
| Multiple subspecialties | 42 (34) |
| Clinical setting, n (%) | |
| ≤4 physicians | 79 (64) |
| >4 physicians | 45 (36) |
| Median (Q1−Q3) self-reported FN risk intervention threshold across all chemotherapy cycles2, % | 20.0 (15.0–20.0) |
FN, febrile neutropenia.
1
Investigator analysis set.
2
The FN risk at which the investigator would consider ordering G-CSF in usual standard practice.